FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

OMB APPROVAL 3235-OMB Number: 0104 Estimated average burden hours per 0.5

response

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A Kardes H		porting Person [*]	2. Date of Requiring (Month/Da 04/20/20	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol Alignment Healthcare, Inc. [ALHC]					
(Last) 1100 W. TO	(First)	(Middle) UNTRY RD.			4. Relationship of Reporting Issuer (Check all applicable)	10% Owner Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year)		
SUITE 1600)		_		Director X Officer (give title below)			(Ch	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting	
ORANGE CA 92868			_		Chief Technolog	y Officer		Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir			4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Common Stock					317,907(1)(2)		D			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion Exercise Price of		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative		Direct (D) or Indirect (I) (Instr. 5)	5)	
Options (Rig	ght to Buy)		(3)	03/25/2031	Common Stock	69,259	18		D	
Options (Right to Buy)		(4)	03/08/2032	Common Stock	36,496	9.00	6	D		

Explanation of Responses:

- 1. Includes (i) 113,657 shares of Common Stock of Alignment Healthcare, Inc. (the "Company"); (ii) 20,566 shares of unvested restricted stock, all of which vest on July 15, 2023; (iii) 20,376 shares of unvested restricted stock, 50% of which vest on each of August 1, 2023 and August 1, 2024; (iv) 10,283 shares of unvested restricted stock, all of which vest on November 19, 2023; (v) 5,500 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company ("RSUs"), granted on March 25, 2021, 25% of which vested or will vest on each of the first four anniversaries of the grant date; (Cont.)
- 2. (Cont. from footnote 1) (vi) 66,000 RSUs granted on April 9, 2021, 25% of which vested or will vest on each of the first four anniversaries of the grant date; (vii) 49,669 RSUs granted on March 8, 2022, 25% of which vested or will vest on each of the first four anniversaries of the grant date; and (viii) 44,482 RSUs granted on September 12, 2022, 50% of which will vest on or about each of the third and fourth anniversaries of the grant date. An aggregate of 12,626 shares have been sold upon vesting of RSÚs in non-discretionary sale-to-cover transactions. In each case, vesting is subject to the reporting person's continued service to the Company as of the applicable vesting date.
- 3. Options vested or will vest 25% on each of the first four anniversaries of the March 25, 2021 grant date, subject to the reporting person's continued service to the Company as of
- 4. Options vested or will vest 25% on each of the first four anniversaries of the March 8, 2022 grant date, subject to the reporting person's continued service to the Company as of the applicable vesting date.

Remarks:

/s/ Richard A. Cross, as Attorney-in-Fact, for

05/01/2023

Hakan Kardes ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of (i) R. Thomas Freeman, (ii) Richard A. Cross and (iii) Thomas E. Mitchell, signing SINGLY, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or holder of 10% or more of the registered class of securities of Alignment Healthcare, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

* * * * *

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of April 2023.

By: /s/ Hakan Kardes

Name: Hakan Kardes